Administration of Recombinant TAPBPL Protein Ameliorates Collagen-Induced Arthritis in Mice.

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease distinguished by synovial hyperplasia and a progressive destruction of joints. T cells are critical players in the pathogenesis of RA. We have previously identified a novel immune checkpoint molecule, TAPBPL, that inhibits T cell functions in vitro. As a model for human RA, we investigated the ability of the TAPBPL protein to ameliorate collagen type II (CII)-induced arthritis (CIA) in mice that were injected with recombinant TAPBPL or a control protein. The mice were analyzed for CIA development, immune cells, and their responses. We found that TAPBPL protein significantly decreased CIA incidence and reduced clinical and pathological arthritis scores, which were related to a lower number of activated CD4 T cells but a greater number of regulatory T cells (Tregs) in the spleen, and a reduction of Th1/Th17 inflammatory cytokines in the joints and serum. Importantly, TAPBPL protein inhibited CII-specific T cell growth and Th1 and Th17 cytokine expression and reduced the production of CII autoantibodies in the serum. Our results suggest that TAPBPL protein can ameliorate CIA in mice and has the potential to be used in the treatment of patients with RA.

• Authors: Zhenzhen Zhang, Jin Zhao, Kuan Chen Lai, Laijun Lai
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 24 Issue 18 (Sep 07 2023) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 37762076 (Publication Type: Journal Article)

Chemical References

• Autoantibodies
• Cytokines
• TAPBPL protein, human
• Immunoglobulins
• Membrane Proteins

Topics

• Humans
• Animals
• Mice
• Arthritis, Experimental (drug therapy)
• Arthritis, Rheumatoid (drug therapy)
• Autoantibodies
• Cytokines
• Hyperplasia
• Immunoglobulins
• Membrane Proteins